Leukemia, Myelogenous, Chronic, BCR-ABL PositiveBenzamidesLeukemia, Myeloid, Chronic-PhasePiperazinesPyrimidinesCytogenetic AnalysisFusion Proteins, bcr-ablPhiladelphia ChromosomeLeukemia, Myeloid, Accelerated PhaseInterferon-alphaHarringtoninesCytogeneticsThiazolesAntineoplastic AgentsProtein Kinase InhibitorsGenes, ablBlast CrisisLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeRemission InductionTreatment OutcomeCytidine MonophosphateArabinonucleotidesDrug Resistance, NeoplasmProtein-Tyrosine KinasesTreatment FailureCytarabineBlood Cell CountSurvival RatePrognosisFollow-Up StudiesNeoplasm, ResidualDisease-Free SurvivalSurvival AnalysisRNA, NeoplasmBone MarrowIn Situ Hybridization, FluorescenceKaryotypingDrug Administration ScheduleChromosome AberrationsChromosome BandingChromosomes, Human, Pair 5Time FactorsMyelodysplastic SyndromesThrombocytopeniaAntineoplastic Combined Chemotherapy ProtocolsSalvage TherapyDose-Response Relationship, DrugPrecursor Cell Lymphoblastic Leukemia-LymphomaHematopoietic Stem Cell TransplantationDisease ProgressionDrug ResistanceRecombinant ProteinsReverse Transcriptase Polymerase Chain ReactionRecurrenceAdministration, OralEnzyme InhibitorsMutationPolymerase Chain ReactionRNA, MessengerRisk Factors